Physician profile
Sherwin Imperio
NPI 1225565104
$8,039.45
in general payments reported to CMS, 2019-2025
22 companies · $467 in 2025
The $467 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,970 · 2022: $1,278 · 2023: $2,458 · 2024: $1,867 · 2025: $467.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,711 · Education: $80.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,710.69 |
| Education | $80.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,793.04 | 2021-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Alkermes, INC. | $1,496.90 | 2021-2024 | Aristada, Lybalvi, Aristada Initio |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $940.88 | 2021-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $826.24 | 2021-2022 | |
| Abbvie INC. | $698.09 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $638.83 | 2022-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $356.55 | 2021-2025 | Austedo Xr, Uzedy, Austedo |
| Vanda Pharmaceuticals INC. | $343.74 | 2021-2025 | Fanapt, Hetlioz |
| Lundbeck LLC | $236.78 | 2022-2024 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $166.36 | 2021-2025 | Rexulti, Abilify Asimtufii |
| Apellis Pharmaceuticals, INC. | $133.30 | 2023 | |
| Corium, LLC | $79.70 | 2024 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $72.20 | 2022-2023 | Trintellix |
| Ironshore Pharmaceuticals INC. | $67.04 | 2023-2024 | Jornay Pm |
| Tris Pharma INC | $34.58 | 2024 | Dyanavel Xr |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $31.84 | 2021-2023 | Loreev Xr |
| Sage Therapeutics, LLC | $30.27 | 2024 | |
| Indivior INC. | $28.13 | 2023 | Perseris |
| Axsome Therapeutics, INC. | $22.34 | 2023 | Auvelity |
| Eisai INC. | $18.01 | 2021 | |
| Novo Nordisk INC | $13.58 | 2025 | Wegovy |
| Supernus Pharmaceuticals, INC. | $11.05 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sherwin Imperio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.